Progress of immunotherapy for multiple myeloma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 5-10, 2021.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-882238
Biblioteca responsável:
WPRO
ABSTRACT
The clinical application of biological immunotherapy such as chimeric antigen receptor T cells (CAR-T) and novel targeted therapy has explored a new therapy for multiple myeloma (MM) treatment. Targeting B-cell maturation antigen (BCMA), allogeneic CAR-T, antibody-drug conjugate (ADC) and bispecific antibody targeting BCMA have achieved remarkable efficacy and safety in many clinical studies. This article introduces the latest immunotherapy for MM at the 62nd American Society of Hematology (ASH) Annual Meeting.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2021
Tipo de documento:
Artigo